CD34 and hemoglobinopathy: A significant increase in HbF levels in the erythroid cells derived from the CD34+ cells transduced with Ery-Lin-shBCL11A LVs suggests that this vector may be suitable for gene therapy applications for hemoglobinopathies after modifications to remove the selection markers.